Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

8Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Advances in cancer immunotherapy over the last decade have led to the development of several agents that affect immune checkpoints. Inhibitory receptors expressed on T cells that negatively regulate the immune response include cytotoxic T‑lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1), which have been studied more than similar receptors. Inhibition of these proteins and other immune checkpoints can stimulate the immune system to attack cancer cells, and prevent the tumor from escaping the immune response. However, the administration of anti-PD1 and anti-CTLA4 antibodies has been associated with adverse inflammatory responses similar to autoimmune diseases. The current review discussed the role of the NF-κB pathway as a tumor promoter, and how it can govern inflammatory responses and affect various immune checkpoints. More precise knowledge about the communication between immune checkpoints and NF-κB pathways could increase the effectiveness of immunotherapy and reduce the adverse effects of checkpoint inhibitor therapy. Graphical abstract: (Figure presented.)

Cite

CITATION STYLE

APA

Ebrahimi, N., Abdulwahid, A. H. R. R., Mansouri, A., Karimi, N., Bostani, R. J., Beiranvand, S., … Aref, A. R. (2024, December 1). Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy. Cellular and Molecular Life Sciences. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s00018-023-05098-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free